Equasens (EQS) | Financial Analysis & Statements
Equasens Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
394.0M
Total Liabilities
166.4M
Shareholders Equity
227.6M
Debt to Equity
0.73
Cash Flow Metrics
Revenue & Profitability Trend
Equasens Income Statement From 2020 to 2025
| Metric | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | - | 219.8M | 214.1M | 193.1M | 171.8M |
| Cost of Goods Sold | - | 69.1M | 68.5M | 59.3M | 52.4M |
| Gross Profit | - | 150.6M | 145.6M | 133.8M | 119.3M |
| Gross Margin % | 0.0% | 68.5% | 68.0% | 69.3% | 69.5% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | - | - |
| Other Operating Expenses | - | 3.7M | 4.2M | 4.1M | 3.6M |
| Total Operating Expenses | 0 | 3.7M | 4.2M | 4.1M | 3.6M |
| Operating Income | - | 55.8M | 56.2M | 50.3M | 46.6M |
| Operating Margin % | 0.0% | 25.4% | 26.3% | 26.0% | 27.2% |
| Non-Operating Items | |||||
| Interest Income | - | 3.9M | 1.6M | 921.0K | 1.3M |
| Interest Expense | - | 669.0K | 679.0K | 589.0K | 571.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | - | 57.4M | 54.4M | 51.9M | 45.9M |
| Income Tax | - | 9.7M | 6.2M | 10.6M | 13.4M |
| Effective Tax Rate % | 0.0% | 16.9% | 11.4% | 20.5% | 29.2% |
| Net Income | - | 48.9M | 48.7M | 41.2M | 32.7M |
| Net Margin % | 0.0% | 22.2% | 22.7% | 21.3% | 19.0% |
| Key Metrics | |||||
| EBITDA | - | 72.2M | 69.5M | 64.4M | 55.7M |
| EPS (Basic) | €2.73 | €3.13 | €3.09 | €2.60 | €2.04 |
| EPS (Diluted) | €2.73 | €3.13 | €3.06 | €2.58 | €2.02 |
| Basic Shares Outstanding | - | 15015974 | 15031697 | 15019717 | 15068964 |
| Diluted Shares Outstanding | - | 15015974 | 15031697 | 15019717 | 15068964 |
Income Statement Trend
Equasens Balance Sheet From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 18.4M | 23.4M | 34.8M | 33.6M | 21.4M |
| Short-term Investments | 36.3M | 44.6M | 30.0M | 29.7M | 29.2M |
| Accounts Receivable | 52.8M | 46.5M | 37.4M | 31.8M | 34.6M |
| Inventory | 10.3M | 9.3M | 8.9M | 6.8M | 4.4M |
| Other Current Assets | - | - | - | 1.0K | - |
| Total Current Assets | 132.2M | 137.2M | 122.3M | 110.9M | 97.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 6.9M | 852.0K | 23.5M | 22.1M | 17.7M |
| Goodwill | 220.5M | 204.6M | 206.9M | 167.7M | 129.5M |
| Intangible Assets | 40.1M | 38.5M | 39.5M | 36.6M | 30.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.0K | - | -1.0K | - | 1.0K |
| Total Non-Current Assets | 261.8M | 213.6M | 207.7M | 184.9M | 160.5M |
| Total Assets | 394.0M | 350.8M | 330.0M | 295.8M | 258.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 16.1M | 16.8M | 16.3M | 14.2M | 13.4M |
| Short-term Debt | 19.1M | 18.1M | 20.7M | 16.8M | 10.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 70.9M | 61.2M | 54.3M | 49.3M | 47.6M |
| Total Current Liabilities | 108.1M | 98.1M | 94.1M | 81.4M | 72.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 46.9M | 48.4M | 59.4M | 55.0M | 47.5M |
| Deferred Tax Liabilities | 1.6M | 1.5M | 1.4M | 855.0K | 635.0K |
| Other Non-Current Liabilities | 2.7M | 97.0K | 325.0K | 4.3M | 1.3M |
| Total Non-Current Liabilities | 58.3M | 55.9M | 70.7M | 65.5M | 54.0M |
| Total Liabilities | 166.4M | 154.0M | 164.7M | 146.8M | 126.2M |
| Equity | |||||
| Common Stock | 3.0M | 3.0M | 3.0M | 3.0M | 3.0M |
| Retained Earnings | 47.0M | 46.4M | 39.1M | 30.7M | 28.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 227.6M | 196.8M | 165.2M | 149.0M | 131.9M |
| Key Metrics | |||||
| Total Debt | 66.0M | 66.5M | 80.0M | 71.8M | 57.5M |
| Working Capital | 24.1M | 39.0M | 28.2M | 29.5M | 25.4M |
Balance Sheet Composition
Equasens Cash Flow Statement From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 55.2M | 55.2M | 50.3M | 46.1M | 40.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 352.0K | 352.0K | - | - | - |
| Working Capital Changes | -2.7M | -6.1M | -4.3M | 6.4M | 3.9M |
| Operating Cash Flow | 52.8M | 49.8M | 46.3M | 52.6M | 44.8M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | 524.0K |
| Acquisitions | -8.3M | 0 | -25.9M | -19.5M | -14.1M |
| Investment Purchases | -58.5M | -24.5M | 0 | 0 | -2.6M |
| Investment Sales | 34.7M | 12.1M | 0 | 0 | 0 |
| Investing Cash Flow | -32.1M | -12.4M | -26.0M | -19.5M | -16.1M |
| Financing Activities | |||||
| Share Repurchases | -5.2M | -7.3M | -5.2M | 0 | - |
| Dividends Paid | -17.3M | -15.8M | -14.3M | -13.5M | -12.8M |
| Debt Issuance | 18.2M | 7.8M | 26.9M | 22.2M | 15.4M |
| Debt Repayment | -20.2M | -17.8M | -15.2M | -11.6M | -8.8M |
| Financing Cash Flow | -19.3M | -35.1M | -9.1M | 5.1M | -17.3M |
| Free Cash Flow | 43.1M | 46.8M | 37.1M | 27.5M | 23.7M |
| Net Change in Cash | 1.4M | 2.2M | 11.3M | 38.2M | 11.4M |
Cash Flow Trend
Equasens Key Financial Ratios
No financial ratio data available.
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| Cegedim S.A | 188.1M | 92.86 | 0.54 | -4.95% | -2.25% | 115.34 |
| Smaio S.A | 47.0M | 16.30 | 5.78 | -24.00% | -22.35% | 41.76 |
| Abl Diagnostics | 44.4M | 92.00 | 5.94 | 6.73% | 7.44% | 38.66 |
| Intrasense S.A | 11.8M | - | - | -314.39% | -244.82% | -0.21 |
| Media Lab S.p.A | 8.1M | 18.89 | 5.88 | 35.13% | 23.18% | - |
Financial data is updated regularly. All figures are in the company's reporting currency.